ImmunityBio, Inc. - IBRX STOCK NEWS

ImmunityBio (NASDAQ: IBRX) and NantOmics announced a new pipeline for identifying neoepitopes and neoepitope-reactive T cells in cancer patients. This methodology aims to personalize immunotherapy by predicting mutated peptide sequences that trigger immune responses. Collaborative efforts with leading institutions have shown promise in previous trials, hinting at improved cancer treatment outcomes. ImmunityBio's approach integrates bioinformatics for neoepitope discovery, potentially enhancing vaccine and cell transfer therapies.

ImmunityBio (NASDAQ: IBRX) has received FDA authorization for a Phase 1b/2 study to assess the safety and efficacy of Anktiva (N-803) and PD-L1 t-haNK cells combined with Trodelvy in advanced triple-negative breast cancer (TNBC) patients. This study aims to evaluate if the combination can enhance Trodelvy's effectiveness in patients who haven't responded to previous treatments. The global incidence of breast cancer was 2.3 million last year, with TNBC being particularly aggressive and accounting for 10-15% of cases. The trial seeks to offer new hope to this patient group.

ImmunityBio (NASDAQ: IBRX) announced the initiation of its HIV clinical pipeline, featuring a study of Anktiva™ (N-803) aimed at controlling HIV after pausing antiretroviral therapy. Sponsored by the NIAID, this trial evaluates Anktiva alone or with broadly neutralizing antibodies (bNABs). A second Phase 2 study will assess Anktiva during acute HIV infection, conducted by the U.S. Military HIV Research Program. Anktiva has shown potential in reversing HIV latency and activating immune responses, presenting a promising avenue for treatment alternatives.

ImmunityBio announced two clinical trials in South Africa to evaluate its hAd5 T-cell-based COVID-19 vaccine. The first trial focuses on using the vaccine as a "Universal Boost" for healthcare workers already vaccinated. The second will assess safety and efficacy after prior COVID-19 infection. Key features include multiple administration methods potentially enhancing access and effectiveness. Preliminary studies in the U.S. show promise with a 10-fold increase in T cell response. Future phases will involve larger participant groups to confirm long-term immunity against variants.

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Founder Dr. Patrick Soon-Shiong will present at the 2021 Jefferies Virtual Healthcare Conference from June 1-4. The presentation, scheduled for June 4 at 11:30 a.m. EDT, will cover updates on the company's infectious disease and oncology programs. Attendees can access a live video webcast via the ImmunityBio Investor Relations website. ImmunityBio is a clinical-stage company focused on immunotherapy, with over 40 clinical trials in various stages, including treatments for cancers and infectious diseases.

ImmunityBio, Inc. (NASDAQ: IBRX) announced a poster presentation on its interleukin-15 superagonist Anktiva® at the upcoming 2021 ASCO Annual Meeting. The Phase 2 study examines Anktiva in combination with checkpoint therapy for patients who relapsed from prior treatments. The study involved 140 participants, showing a 68% disease control rate (82 out of 121 evaluable) and favorable toxicity compared to traditional therapies. The data suggests potential long-term benefits in multiple cancers, marking a significant step towards a chemotherapy-free immunotherapy approach.

ImmunityBio has received FDA authorization for a Phase 1 study evaluating its m-ceNK™ platform combined with Anktiva (N-803) in patients with advanced solid tumors. This novel approach utilizes NK cells from patients, enhanced with cytokines, to target cancer effectively. The trial will involve two cohorts: one with newly diagnosed patients and another with those who have undergone at least two prior therapies. This innovative therapy aims to significantly impact the clinical landscape of solid tumors, which constitute a large share of cancer diagnoses in the U.S.

ImmunityBio (NASDAQ: IBRX) has initiated preclinical development of its liquid tumor pipeline, featuring Anktiva™ (N-803) in a Phase 1 study. Results published in the Clinical Cancer Research journal indicate that Anktiva combined with Rituxan® shows promising safety and efficacy in patients with indolent non-Hodgkin lymphoma (iNHL) post two lines of therapy. Key findings include a 78% overall response rate in subcutaneous administration and 100% complete response in sensitive cases. The study suggests Anktiva's potential to enhance therapeutic monoclonal antibody activity across various tumor types.

ImmunityBio has initiated a Phase 2 clinical trial in Thailand for its interleukin-15 superagonist Anktiva® (N-803) in combination with antiretroviral therapy to combat HIV. Conducted by the U.S. Military HIV Research Program, the study aims to evaluate its effectiveness in inhibiting HIV reservoirs during acute infection. Preliminary Phase 1 data indicated Anktiva's safety and efficacy in activating immune responses. The 12-week study will assess immunostimulatory effects and viral load reduction.